Improving multivariable prostate cancer risk assessment using the Prostate Health Index

BJU International

Volumn 117, Issue 3, 2016, Pages 409-417

  Foley, Robert W ^a   Gorman, Laura ^a   Sharifi, Neda ^b   Murphy, Keefe ^a   Moore, Helen ^b   Tuzova, Alexandra V ^c   Perry, Antoinette S ^c   Murphy, T Brendan ^a   Lundon, Dara J ^a,d   Watson, R William G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

biomarkers; biopsy; p2PSA; predictive models; Prostate Health Index; prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IRISH (CITIZEN); LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; AREA UNDER THE CURVE; CANCER GRADING; CLINICAL TRIAL; EARLY CANCER DIAGNOSIS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

AREA UNDER CURVE; BIOPSY, NEEDLE; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84959294371     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13143     Document Type: Article

References (30)

1. National Cancer Registry. Cancer in Ireland 1994-2011: Annual Report of the National Cancer Registry 2014, 2014. Available at: http://www.ncri.ie/sites/ncri/files/pubs/annualreport2014.pdf. Accessed July 2014
2. Irish National Cancer Control Programme. nccP Prostate Cancer Referral Guideline, 2011. Available at: http://www.healthlink.ie/Oncology/NCCPProstateCancerReferralGuidelineVersion1.3January2011.pdf. Accessed July 2014
3. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013; 64: 876-92
4. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-37
5. Murphy DG, Ahlering T, Catalona WJ, et al. The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int 2014; 113: 186-8
6. Van Vugt HA, Roobol MJ, Busstra M, et al. Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int 2012; 109: 1480-8
7. Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004; 50: 1017-25
8. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004; 171 (6 Pt 1): 2239-44
9. Fossati N, Lazzeri M, Haese A, et al. Clinical performance of serum isoform [-2]proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age: results from a multicentric European study. BJU Int 2015; 115: 913-20
10. Mearini L, Ferri C, Lazzeri M, et al. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Urol Int 2014; 93: 135-45
11. Perdonà S, Bruzzese D, Ferro M, et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013; 73: 227-35
12. Ferro M, Bruzzese D, Perdonà S, et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One 2013; 8: e67687
13. Chun FK-H, Briganti A, Graefen M, et al. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol 2007; 52: 436-44
14. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60: 214-22
15. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-42
16. Nguyen CT, Kattan MW. How to tell if a new marker improves prediction. Eur Urol 2011; 60: 226-30
17. Vickers AJ, Cronin AM. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. Semin Oncol 2010; 37: 31-8
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45
19. PCPT. Individualized Risk Assessment of Prostate Cancer, 2014. Available at: http://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp. Accessed July 2014
20. R Core Team. R: A Language and Environment for Statistical Computing. Austria: Foundation for Statistical Computing, 2014
21. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77
22. Fox J, Weisberg S. An R Companion to Applied Regression, 2nd edn. Thousand Oaks, CA: Sage, 2011
23. Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013; 63: 986-94
24. Loeb S, Sokoll LJ, Broyles DL, et al. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol 2013; 189: 1702-6
25. Lughezzani G, Lazzeri M, Larcher A, et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 2012; 188: 1144-50
26. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650-5
27. Jansen FH, van Schaik RHN, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921-7
28. Roobol M, Azevedo N. The rotterdam prostate cancer risk calculator: improved prediction with more relevant pre-biopsy information, now in the palm of your hand. J Urol 2014; 191: e546-7
29. Roemeling S, Schröder FH. Words of wisdom. Re: Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. Eur Urol 2008; 53: 663-4
30. Numao N, Kawakami S, Sakura M, et al. Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy. BJU Int 2012; 109: 665-71